Term
|
Definition
| anticholinergic drug (antiparkinson drug) |
|
|
Term
|
Definition
| anticholinergic drug (antiparkinson drug) |
|
|
Term
|
Definition
| anticholinergic drug (antiparkinson drug) |
|
|
Term
|
Definition
| anticholinergic drug (antiparkinson drug) |
|
|
Term
|
Definition
| anticholinergic drug (antiparkinson drug) |
|
|
Term
|
Definition
| #1 drug used to treat Parkinsons Disease, immediate precurso of dopamine |
|
|
Term
|
Definition
| Vitamine B6 (cofactor for L-aromatic amino acid decarboxylase, increases the peripheral decarboxylation of L-DOPA) |
|
|
Term
|
Definition
| inhibit oxidative deamination of DA and NE and increase peripheral cardiovascular side effects of L-Dopa |
|
|
Term
|
Definition
| DA receptor antagonists and can prevent the antiparkinson effects of DA derived from L-DOPA |
|
|
Term
|
Definition
| dopa decarboxylase inhibitor that inhibits conversion of L-DOPA to DA; increases antiparkinson effect of L-DOPA (more penetrates BBB) |
|
|
Term
|
Definition
| MAOb inhibitor that prevents oxidative deamination of dopamine, increases antiparkinson effect of L-DOPA |
|
|
Term
|
Definition
| MAOb inhibitor that prevents oxidative deamination of dopamine, increases antiparkinson effect of L-DOPA |
|
|
Term
|
Definition
| COMT inhibitor that prevents peripheral metabolism of L-DOPA; increases antiparkinson effect of carbidopa/L-DOPA |
|
|
Term
|
Definition
| COMT inhibitor that prevents peripheral metabolism of L-DOPA; increases antiparkinson effect of carbidopa/L-DOPA |
|
|
Term
| carbidopa/L-DOPA/entacapone |
|
Definition
| COMT inhibitor that prevents peripheral metabolism of L-DOPA; increases antiparkinson effect of carbidopa/L-DOPA (carbidopa cannot cross BBB, allows more L-DOPA to cross barrier before being converted to DA) |
|
|
Term
|
Definition
| ergot agonists at D1 receptor; used as adjunct therapy to reduce dose of L-DOPA |
|
|
Term
|
Definition
| non-ergot agonist at D3 receptor; excreted unchanged in urine |
|
|
Term
|
Definition
| non-ergot agonist at D2 receptor; metabolized by liver |
|
|
Term
|
Definition
| 24-hour continuous delivery system (antiparkinson drug) |
|
|
Term
|
Definition
| indirect dopamine receptor agonist; antiviral drug for influenza A2; releases DA from nerve endings in cases of mild parkinsonism |
|
|
Term
|
Definition
| reserpine-like DA depleting agent (used in Huntington's disease) |
|
|
Term
|
Definition
| DA receptor antagonist (used in Huntington's disease) |
|
|
Term
|
Definition
| DA stabilizer in clinical trials (used in Huntington's disease) |
|
|
Term
|
Definition
| AChE-inhibitor (experimental) (used in Huntington's disease) |
|
|
Term
|
Definition
| classical (conventional) neuroleptics |
|
|
Term
|
Definition
| classical (conventional) neuroleptics |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| benzodiazepine (anxiolytic drug)(intermediate onset, long duration of action, long-lived active metabolites) |
|
|
Term
|
Definition
| benzodiazepine (anxiolytic drug)(fast onset, long duration of action, long-lived active metabolites) |
|
|
Term
|
Definition
| benzodiazepine (anxiolytic drug)(slow onset, short duration of action) |
|
|
Term
|
Definition
| benzodiazepine (anxiolytic drug) (intermediate onset, short duration of action) |
|
|
Term
|
Definition
| benzodiazepine (anxiolytic drug)(intermediate onset, short duration of action) |
|
|
Term
|
Definition
| blocks agonists and inverse agonists of benzodiazepines |
|
|
Term
|
Definition
| an azaspirodecanedione, agonist at presynaptic 5-HT(1A) receptors |
|
|
Term
|
Definition
| secondary amine tricyclic antidepressant |
|
|
Term
|
Definition
| secondary amine tricyclic antidepressant |
|
|
Term
|
Definition
| tetracyclic antidepressant |
|
|
Term
|
Definition
| tertiary amine tricyclic antidepressant |
|
|
Term
|
Definition
| tertiary amine tricyclic antidepressant |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| SSRI antidepressant (lowest sexual dysfunciton SE) |
|
|
Term
|
Definition
| atypical antidepressant (NDRI) |
|
|
Term
|
Definition
| atypical antidepressant (SARI) |
|
|
Term
|
Definition
| atypical antidepressant (SARI) |
|
|
Term
|
Definition
| atypical antidepressant (SNRI) |
|
|
Term
|
Definition
| atypical antidepressant (NaSSA) |
|
|
Term
|
Definition
| irreversible and non-selective MAO-inhibitor |
|
|
Term
|
Definition
| irreversible and non-selective MAO-inhibitor |
|
|
Term
|
Definition
| irreversible and non-selective MAO-inhibitor |
|
|
Term
|
Definition
| irreversible and non-selective MAO-inhibitor |
|
|
Term
|
Definition
| mood stabilizer and antimanic drug |
|
|
Term
| valproic acid, lamotrigine, quetiapine, ziprasidone, aripiprazole, fluoxetine/olanzapine |
|
Definition
| FDA approved drugs with antimanic activity |
|
|
Term
|
Definition
| unlabelled use in manic syndrome |
|
|
Term
| dextroamphetamine or dexamphetamine |
|
Definition
| amphetamine derivative (stimulant drug)- more potent centrally |
|
|
Term
|
Definition
|
|
Term
|
Definition
| amphetamine derivative (stimulant drug)- more potent peripherally |
|
|
Term
|
Definition
| amphetamine derivative (stimulant drug) |
|
|
Term
|
Definition
| amphetamine derivative (stimulant drug) |
|
|
Term
|
Definition
| non-amphetamine stimulant |
|
|
Term
|
Definition
| non-amphetamine stimulant |
|
|
Term
|
Definition
| phenylethylamine anorexiants (caused hemorrhagic stroke) |
|
|
Term
|
Definition
| phenylethylamine anorexiants (caused heart valve disease) |
|
|
Term
|
Definition
| combination of either enfluramine or dexfenfluramine plus the amphetamine-like drug phentermine (caused heart valve damage and primary pulmonary hypertension) |
|
|
Term
|
Definition
| stimulates the endogenous cannabinoid receptors CB1 and CB2; mimics the pharmacological effects of endocannabinoids |
|
|
Term
| synthetic THC(dronabinol, Marinol) |
|
Definition
|
|
Term
| synthetic nabilone (Cesamet) |
|
Definition
| analog of dronabinol; cannabinoid drug |
|
|
Term
|
Definition
| withdrawn from market; inverse agonist at CB1 receptor, causes reduction in appetite, increased risk of diabetes 2 and dyslipidemia |
|
|
Term
|
Definition
| inhibition of nerve conduction, inhibition of catecholamine reuptake mechanism, unspecified influences on brain serotonin mechanisms |
|
|
Term
|
Definition
| psychedelic (hallucinogen) |
|
|
Term
| lysergic acid diethylamide |
|
Definition
| psychedelic (hallucinogen) |
|
|
Term
|
Definition
| psychedelic (hallucinogen) |
|
|
Term
|
Definition
| dissociative (hallucinogen) |
|
|
Term
|
Definition
| dissociative (hallucinogen) |
|
|
Term
|
Definition
| dissociative (hallucinogen) |
|
|
Term
|
Definition
| dissociative (hallucinogen) |
|
|
Term
|
Definition
| deliriants (hallucinogens) |
|
|
Term
|
Definition
| phenothiazine (typical antipsychotic); high SED and OH |
|
|
Term
|
Definition
| phenothiazine (typical antipsychotic); high antipsychotic potency and EPS, low SED, AC, OH |
|
|
Term
|
Definition
| phenothiazine (typical antipsychotic); high SED, AC, low EPS |
|
|
Term
|
Definition
| Butyrophenone (typical antipsychotic), high AP, EPS, low SED, AC, OH |
|
|
Term
|
Definition
| Atypical Antipsychotic (weight gain and sedation) |
|
|
Term
|
Definition
| Atypical Antipsychotic. High Sedation |
|
|
Term
|
Definition
| Atypical Antipsychotic (high weight gain) |
|
|
Term
|
Definition
| Atypical Antipsychotic (high sedation) |
|
|
Term
|
Definition
| Atypical Antipsychotic (low sedation and weight gain) |
|
|
Term
|
Definition
| Atypical Antipsychotic (low weight gain and sedation) |
|
|
Term
| cholinesterase inhibitors |
|
Definition
|
|
Term
|
Definition
| cholinesterase inhibitor (mild-to-moderate alzheimers) |
|
|
Term
|
Definition
| cholinesterase inhibitor (used in mild-to-severe alzheimer's) |
|
|
Term
|
Definition
| cholinesterase inhibitor (mild-to-moderate alzheimers |
|
|
Term
|
Definition
| prevention of glutamate excitotoxicity (used in dementia) |
|
|
Term
|
Definition
| NMDA antagonist (used in moderate-to-severe Alzheimer's) adverse effects: confusion, dizziness, drowsiness |
|
|
Term
|
Definition
| neuroprotective effect against oxidative stress (Vitamin E = not approved) |
|
|
Term
|
Definition
| approved to reduce sleep attacks in narcolepsy |
|
|
Term
|
Definition
| selective NE reuptake inhibitor (non-stimulant approved for the treatment of ADHD in children, adolescents, and adults) |
|
|
Term
|
Definition
| Irreversible and non-selective MAO-inhibitor (hydrazine) |
|
|
Term
| tranylcypromine (parnate) |
|
Definition
| irreversible and non-selective MAO-inhibitor (non-hydrazine) |
|
|
Term
|
Definition
| reversible inhibitor of MAOa (RIMA) |
|
|
Term
|
Definition
| reersible inhibitor of MAOa (RIMA) |
|
|
Term
| MAO inhibitors + meperidine |
|
Definition
| paradoxical CNS excitation |
|
|
Term
| MAO inhibitor + sympathomimetic amine-containing medicines or tyramine-containing foods |
|
Definition
| acute hypertensive crisis |
|
|
Term
| Carbamazepine drug action |
|
Definition
| decreases NE release (stimulation of presynaptic adenosine receptors) |
|
|
Term
|
Definition
| acts on CB1 and CB2 receptors |
|
|
Term
| 2-arachidonoylglycerol (2-AG) |
|
Definition
|
|
Term
| N-arachidonoyldopamine (NADA) |
|
Definition
|
|
Term
|
Definition
| antidotal therapy for psychedelics (blocks both DA/SER) |
|
|
Term
| ketamine (prototype)- MAO |
|
Definition
| blocks NMDA receptor (reduction in pain but can't figure out where its coming from) |
|
|
Term
|
Definition
| PCP-MOST DANGEROUS (acure toxicity, combtiveness, catatonia, convulsions, coma) |
|
|
